SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
October 16, 2006
----------------
Date of Report
(Date of Earliest Event Reported)
LIPIDVIRO TECH, INC.
--------------------
(Exact Name of Registrant as Specified in its Charter)
NEVADA 000-49655 87-0678927
------ --------- ----------
(State or other (Commission File No.) (IRS Employer I.D. No.)
Jurisdiction)
1338 South Foothill Blvd. #126
Salt Lake City, Utah 84108
--------------------------
(Address of Principal Executive Offices)
(801) 583-9900
--------------
Registrant's Telephone Number
N/A
---
(Former Name or Former Address if changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the Registrant under any of
the following provisions (see general instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
At our Board of Directors meeting held October 16, 2006, we elected Steve
Keyser as the Chairman of the Board of Directors.
Mr. Keyser joins the Company bringing 24 years of experience in private
equities research and asset management. Mr. Keyser's research and analysis
experience spans multiple industries, including biotech and healthcare. Mr.
Keyser founded LipidViro Tech in 2003 and now joins the Company as Chairman of
the Board of Directors.
On October 23, 2006, our Board of Directors appointed Linda C. Sharkus,
Ph.D., to the Board of Directors.
Dr. Sharkus, is President of Acquis Associates, Inc., an executive search
firm that specializes in the Chemical and Allied Industries; she also serves
as a management consultant for emerging companies providing editorial
advertising through Global Media Fund, independent equity research and
assistance in identifying sources of financing. Dr. Sharkus specialized in
her over 20 years professional experience in biotechnology and chemical and
polymer industry, which allow her to advise clients with in-depth
understanding of business management, with particular strength in technology.
Prior to her work in recruitment, she was a scientist at Rohm and Haas in
Biocides/Industrial Chemicals and impact modifiers for PVC in their Plastics
Division. She has a B. S. Degree in Chemistry from Boston College and a Ph.D.
in Organic Chemistry from University of California, Davis. She is a member
of the Society of Human Resources Management and the American Chemical
Society.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
LIPIDVIRO TECH, INC.
Date: 10/25/2006 /s/ Kennneth Hamik
---------- ----------------------------
Kenneth Hamik, President, CEO and
Director